Diabetic Ketoacidosis News and Research

RSS

Diabetic ketoacidosis – (DKA) or diabetic coma occurs when a diabetic does not properly balance their insulin intake with their diet or activity.

Study reveals how SGLT2 inhibitors improve failing heart function

Researchers have discovered that SGLT2 inhibitors, a class of drugs originally developed to treat diabetes and now widely used for heart failure, work by activating a key enzyme that helps heart cells produce and use energy more efficiently.

27 Aug 2026

Trial supports glargine use in resource-limited Type 1 diabetes care

A trial led by University of Pittsburgh researchers and published today in The Lancet Diabetes & Endocrinology adds nuance to the question of whether older human insulins are as effective as insulin analogues in low-resource settings.

6 Jul 2026

The importance of ketones from a clinical and medical perspective

In this interview, News-Medical talks to Marcin Pacek, senior director of medical and scientific affairs in Europe for Nova Biomedical, about the importance of ketones in a medical and clinical setting.

From Nova Biomedical 15 Jun 2026

Study supports routine childhood screening for type 1 diabetes

For ten years, the Fr1da study, coordinated by Helmholtz Munich, has been investigating whether early stages of type 1 diabetes in children can be detected in routine pediatric care.

21 May 2026

AI-driven model predicts type 1 diabetes risk with greater accuracy

Researchers use machine learning and genetic analysis to uncover type 1 diabetes risk factors, improving prediction accuracy and identifying patient subtypes.

5 May 2026

T1GRS model enhances prediction of genetic risk for Type 1 diabetes

In people with Type 1 diabetes (T1D), the immune system shuts down the body's ability to make the hormone insulin, responsible for regulating blood sugar and providing cells with glucose to produce energy.

30 Apr 2026

GLP-1 drugs cut heart and kidney risks in type 1 diabetes study

In a large target trial emulation of 174,678 people with type 1 diabetes, GLP-1 receptor agonist initiation was associated with lower risks of major cardiovascular events and end-stage kidney disease over five years. The study also found no increased risk of hospitalization for diabetic ketoacidosis or severe hypoglycemia, supporting further randomized trials of GLP-1RAs as adjunctive therapy in type 1 diabetes.

22 Mar 2026

Could GLP-1 drugs help curb addiction? Large veteran study points to potential benefit

A large cohort study of more than 600,000 US veterans with type 2 diabetes found that initiating GLP-1 receptor agonists was associated with lower risks of developing substance use disorders compared with SGLT-2 inhibitors. Among veterans with existing substance use disorders, GLP-1 receptor agonist use was also linked to fewer overdose events, hospitalizations, and suicide-related outcomes.

8 Mar 2026

Landmark UK study supports nationwide screening for childhood type 1 diabetes

A landmark UK study involving tens of thousands of families has shown that childhood screening for type 1 diabetes is effective, laying the groundwork for a UK-wide childhood screening program.

20 Jan 2026

Study shows benefits of telemedicine for people with type 1 diabetes

People with type 1 diabetes achieved significantly better long-term blood glucose when their levels were monitored by healthcare professionals in real time, via a sensor under the skin, and they received regular advice in their daily lives.

4 Nov 2025

Reducing ketone levels and increasing exercise capacity could help manage diabetic ketoacidosis

A researcher at the University of Houston finds management of diabetic ketoacidosis may center around reducing ketone levels in diabetic patients and increasing exercise capacity for better health outcomes.

30 Oct 2025

Precision probiotics lower blood sugar and cholesterol in mice

Researchers developed a precision probiotic cocktail comprising three Lactobacillus strains that improved glucose control, reduced weight gain, and lowered cholesterol levels in mice fed a high-fat diet. Metabolomic and microbiome analyses revealed host metabolic adaptations and beneficial shifts in gut bacteria, highlighting translational potential for future clinical trials.

28 Sep 2025

Scientists outline how future therapies could change type 1 diabetes care

Researchers writing in The Lancet review breakthroughs in type 1 diabetes treatment, from immunotherapies that delay onset to stem-cell β-cell replacement and automated insulin delivery. They stress that equitable access, validated surrogate endpoints, and scalable technologies are crucial for lasting impact.

24 Sep 2025

Fasting supports type 1 diabetes care by reshaping the microbiome

A week of fasting alters the gut microbiome in type 1 diabetes, aligning it with healthy profiles and enhancing cholesterol and weight management.

20 Aug 2025

Leptin could offer alternative to insulin for managing type 1 diabetes complication

More than a decade ago, researchers found that an acute complication of type 1 diabetes, diabetic ketoacidosis (DKA), can be resolved with the hormone leptin, even in the absence of insulin.

4 Aug 2025

New study shows brain's role in diabetic ketoacidosis

More than a decade ago, researchers found that an acute complication of type 1 diabetes, diabetic ketoacidosis (DKA), can be resolved with the hormone leptin, even in the absence of insulin.

1 Aug 2025

NIH awards major grant to advance mucormycosis research

The Lundquist Institute for Biomedical Innovation at Harbor-UCLA (TLI) announced today that the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has awarded a new grant (P01AI186818) to Dr. Ashraf S. Ibrahim, PhD, a TLI Investigator, a Professor of Medicine at David Geffen School of Medicine at UCLA, and a leading authority on mucormycosis pathogenesis.

15 Jul 2025